Annovis Bio, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Annovis Bio, Inc. (ANVS) on March 23, 2026. The report discloses a material change in executive leadership effective as of the filing date.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance changes rather than financial performance.
Material Changes
- Departure of CFO: Mark Guerin is no longer employed as Chief Financial Officer effective March 23, 2026.
- Reason for Departure: The departure did not arise from any disagreement with the Company regarding operations, policies, or practices.
- Interim Appointment: Maria Maccecchini, the Company's Chief Executive Officer, has been appointed as Acting Chief Financial Officer until a permanent replacement is identified.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or specific risk factors beyond the standard disclosure of the executive departure. No unusual items or contingencies were reported in this document.
Investor Verification Checklist
- Confirm the timeline for the search and appointment of a permanent Chief Financial Officer.
- Review subsequent filings for any impact on the Company's financial reporting schedule or internal controls.
- Verify if the departure of Mr. Guerin coincides with any other undisclosed operational changes.